LAZ Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Lazard is not a strong buy right now for a beginner long-term investor, even with $50,000-$100,000 to deploy. The stock is trading near resistance in pre-market at 48.55, and the technical setup is only mildly constructive rather than decisive. Analyst sentiment is mixed to cautious, with several target cuts and multiple Neutral/Underweight/Sell views offset by a few Buy/Outperform calls. Options sentiment is bullish on paper, but that appears more like speculative positioning than a clear long-term confirmation. With no fresh news, no insider or congressional buying signal, and no usable latest-quarter financial snapshot, the overall setup does not justify an immediate buy. My direct view: hold off for now; this is not a buy-now name based on the current data.
LAZ is in a pre-market session at 48.55, slightly above the pivot level of 47.678 and below the first resistance at 49.256. MACD histogram is positive and expanding, which supports short-term upward momentum, but RSI_6 at 56.3 is only neutral and moving averages are merely converging rather than showing a strong breakout trend. That means the chart is improving, but not enough to call it a clean entry. The nearby upside is limited unless it can clear 49.26 and then 50.23. The pattern-based outlook is also mixed, with estimated downside over the next week outweighing the near-term setup.
["Argus maintained a Buy rating and expects better M&A activity in 2026 and 2027.", "Asset management AUM rose 15%, showing healthy growth in that segment.", "Positive MACD momentum suggests the stock is trying to improve technically.", "Options positioning is call-heavy, indicating bullish market sentiment."]
["No news in the recent week, so there is no immediate event-driven catalyst.", "Several analysts lowered price targets recently, including UBS and Morgan Stanley.", "Keefe Bruyette downgraded the stock to Market Perform from Outperform.", "Goldman Sachs keeps a Sell rating, and Morgan Stanley keeps an Underweight rating.", "Financial advisory activity was weaker than expected due to delayed deal closures.", "Pattern-based stock trend implies potential short-term downside."]
The latest-quarter financial snapshot was not available due to a data error, so a full quarter-by-quarter review cannot be completed. The only meaningful operating detail provided is that asset management AUM increased 15%, which is a positive growth signal for that segment. However, financial advisory activity was weaker than expected because of delayed deal closures, suggesting the core advisory business remains under pressure. For a long-term buyer, that makes growth quality uneven rather than clearly strong.
Analyst sentiment has turned more cautious recently. Target cuts came from UBS, Morgan Stanley, and Keefe Bruyette, while Argus lowered its target to $52 from $63 but kept a Buy rating. Goldman Sachs remains Sell, Morgan Stanley remains Underweight, UBS is Neutral, and Keefe Bruyette is Market Perform. The Street view is split, but the balance of opinions is more cautious than bullish. Pros: improving AUM, possible M&A rebound in 2026-2027, and some analysts still see upside. Cons: weak advisory activity, several lowered targets, and multiple non-bullish ratings. Overall, Wall Street is not strongly supportive of a buy-it-now stance.
